Journals / Türk Oftalmoloji Dergisi / 2014 / Cilt: 44 - Sayı: 2

Psikotropik ilaçlar ve oküler yan etkileri

Psychotropic drugs and ocular side effects

Pages
144–150
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

If the doctor and the patients are informed about the eye problems related to the use of psychotropic drugs, potential ocular complications can be easily prevented, supervised, and controlled and can even be reversed. (Turk J Ophthalmol 2014; 44: 144-50)

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Nowadays, the number of patients using the types of drugs in question here has significantly increased.
📊
Key Findings & Data:A study carried out in relation with the long-term use of psychotropic drugs shows that the consumption of this group of drugs has substantially increased in terms of variety and quantity.
💡
Conclusion & Impact:If the doctor and the patients are informed about the eye problems related to the use of psychotropic drugs, potential ocular complications can be easily prevented, supervised, and controlled and can even be reversed. (Turk J Ophthalmol 2014; 44: 144-50)
🔬Design:Review & Systematic Survey
📍Scope:2014 Verileri
⚙️Variables:Domain Parameters

Abstract

Nowadays, the number of patients using the types of drugs in question here has significantly increased. A study carried out in relation with the long-term use of psychotropic drugs shows that the consumption of this group of drugs has substantially increased in terms of variety and quantity. In this paper, we present our review of the literature pertaining to ocular complications of psychotropic drugs in long-term treatment profile of numerous patients. If the doctor and the patients are informed about the eye problems related to the use of psychotropic drugs, potential ocular complications can be easily prevented, supervised, and controlled and can even be reversed. (Turk J Ophthalmol 2014; 44: 144-50)

Özet

Günümüzde kronik ilaç kullanan hasta sayısı önemli derecede artmıştır. Uzun süreli psikotrop ilaç kullanımı açısından yapılan bir çalışma, hem çeşitlilik hem de miktar açısından bu grup ilaç tüketiminin önemli derecede arttığını göstermektedir. Bu derleme günümüzde çok sayıda hastanın uzun süreli tedavi profilinde yer alan psikotrop ilaçların oküler komplikasyonlarına ilişkin literatür taraması sonucu hazırlanmıştır. Hekim ve hastalar psikotrop ilaç kullanımına bağlı göz problemleri açısından bilgili oldukları takdirde potansiyel oküler komplikasyonlar kolayca önlenebilir, gözlem ve kontrol altına alınabilir ve hatta geriye döndürülebilirler. (Turk J Ophthalmol 2014; 44: 144-50)

🔖

Cite This Article

AYKAN, Ü., SÖNMEZ, İ. (2022). Psikotropik ilaçlar ve oküler yan etkileri. Türk Oftalmoloji Dergisi, Cilt: 44 - Sayı: 2, 144–150. https://ajindex.com/articles/638080

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (20)

  1. Li J, Tripathi RC, Tripathi BJ. Drug-induced ocular disorders. Drug Saf. 2008;31:127-41
  2. Bond WS, Yee GC. Ocular and cutaneous effects of chronic phenothiazine therapy. Am J Hosp Pharm. 1980;37:74-8
  3. Johnson AW, Buffaloe WJ. Chlorpromazine epithelial keratopathy. Arch Ophthalmol. 1966;76:664-7
  4. Edler K, Gottfries CG, Haslund J, Ravn J. Eye changes in connection with neuroleptic treatment especially concerning phenothiazines and thioxanthenes. Acta Psychiatr Scand. 1971;47:377-84
  5. Hansen TE, Casey DE, Hoffman WF. Neuroleptic intolerance. Schizophr Bull. 1997;23:567-82
  6. Oshika T. Ocular adverse effects of neuropsychiatric agents: incidence and management. Drug Saf. 1995;12:256-63
  7. Feldman PE, Frierson BD. Dermatological and ophthalmological changes associated with prolonged chlorpromazine therapy. Am J Psychiatry. 1964;121:187-8
  8. Greiner AC, Berry K. Skin pigmentation and corneal and lens opacities with prolonged chlorpromazine therapy. Can Med Assoc J. 1964;90:663-5
  9. Satanove A. Pigmentation due to phenothiazines in high and prolonged dosage. JAMA. 1965;191:263-8
  10. Siddall JR. Ocular complications related to phenothiazines. Dis Nerv Syst. 1968;29:Suppl:10-3
  11. Shahzad S, Suleman MI, Shahab H, et al. Cataract occurrence with antipsychotic drugs. Psychosomatics. 2002;43:354-9
  12. Jhee SS, Zarotsky V, Mohaupt SM, Yones CL, Sims SJ. Delayed onset of oculogyric crisis and torticollis with intramuscular haloperidol. Ann Pharmacother. 2003;37:1434-7
  13. Siddall JR. Ocular toxic changes associated with chlorpromazine and thioridazine. Can J Ophthalmol. 1966;1:190-8
  14. Hagopian Y, Stratton DB, Busiek RD. Five cases of pigmentary retinopathy associated with thioridazine administration. Am Am J Psychiatry. 1966;123:97-100
  15. Meredith TA, Aaberg TM, Willerson WD. Progressive chorioretinopathy after receiving thioridazine. Arch Ophthalmol. 1978;96:1172-6
  16. Legros J, Rosner I, Berger C. Ocular effects of chlorpromazine and oxypertine on beagle dogs. Br Br J Ophthalmol. 1971;55:407-15
  17. Seroquel_ (quetiapine) [package insert]. Wilmington (DE); Zeneca Pharmaceuticals, 2001
  18. Stip E, Boisjoly H. Quetiapine: are we overreacting in our concern about cataracts (the beagle effect)? Can J Psychiatry. 1999;44:503
  19. Borovik AM, Bosch MM, Watson SL. Ocular Pigmentation Associated With Clozapine. Med J Aust. 2009;190:210-1
  20. Stratos AA, Peponis VG, Portaliou DM, Stroubini TE, Skouriotis S, Kymionis GD. Secondary Pseudomyopia Induc